

TIGIT inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/TA2639D365D5EN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: TA2639D365D5EN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "TIGIT inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 14+ companies and 18+ pipeline drugs in TIGIT inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TIGIT inhibitors Understanding

TIGIT inhibitors: Overview

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain. It is expressed on activated and memory T cells, NK cells, and Tregs. Binding to either of its two ligands on APCs, CD155 (PVR: poliovirus receptor) and CD112 (PVRL2, nectin-2), prevents their maturation and confers a tolerogenic phenotype. Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. Mechanistically, research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also

inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TIGIT inhibitors R&D. The therapies under development are focused on novel approaches for TIGIT inhibitors.

TIGIT inhibitors Emerging Drugs Chapters

This segment of the TIGIT inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TIGIT inhibitors Emerging Drugs

Tiragolumab: Genentech

Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. By binding to TIGIT, tiragolumab blocks its interaction with a protein called poliovirus receptor (PVR, or CD155) that can suppress the body's immune response. Blockade of TIGIT and PD-L1 may synergistically enable the re-activation of T cells and enhance NK cell antitumor activity.

Ociperlimab: BeiGene

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact IgG Fc binding region for optimal antibody-mediated anti-tumor activity. Ociperlimab binds to TIGIT and blocks its interactions with the poliovirus receptor (CD155) and poliovirus receptor-related 2 (CD112) ligands on tumor cells, resulting in activation of T cell mediated antitumor immune responses.

Further product details are provided in the report.....

TIGIT inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different TIGIT inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TIGIT inhibitors

There are approx. 14+ key companies which are developing the TIGIT inhibitors. The companies which have their TIGIT inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Genentech.

Phases

DelveInsight's report covers around 18+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

TIGIT inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIGIT inhibitors: Pipeline Development Activities

TIGIT inhibitors - Pipeline Insight, 2022

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIGIT inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIGIT inhibitors drugs.

TIGIT inhibitors Report Insights

- TIGIT inhibitors Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

TIGIT inhibitors Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing TIGIT inhibitors drugs?

How many TIGIT inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIGIT inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIGIT inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TIGIT inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Genentech

BeiGene

Arcus Biosciences

iTeos Therapeutics

Merck KGaA

Curocell

Agenus

Compugen

Tasrif Pharmaceutical

Y-Biologics

Aurigene

Mereo BioPharma

Phio pharmaceuticals

Bio-Thera Solutions

Key Products

Tiragolumab

Ociperlimab

Domvanalimab

EOS 448

Etigilimab

AGEN 1307

PH 804-TME

PH 804-ACT

BAT6005

Vibostolimab

M-6223

MK-7684A

COM 902

CRC 01

YBL 027

YBL 012

AUNP-12

TSRF 786C

AB 308

AGEN 1777

Contents

- Introduction
- Executive Summary
- TIGIT inhibitors: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- TIGIT inhibitors – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- Tiragolumab: Genentech
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- MK-7684A: Merck
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- M 6223: Merck
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products

Comparative Analysis
TSRF 786C: Tasrif Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
TIGIT inhibitors Key Companies
TIGIT inhibitors Key Products
TIGIT inhibitors- Unmet Needs
TIGIT inhibitors- Market Drivers and Barriers
TIGIT inhibitors- Future Perspectives and Conclusion
TIGIT inhibitors Analyst Views
TIGIT inhibitors Key Companies
Appendix

I would like to order

Product name: TIGIT inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/TA2639D365D5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TA2639D365D5EN.html>